Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188069 | 0.83 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL28366757 | 0.83 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL16237419 | 0.81 | DDAH1 (0.62) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL31155591 | 0.79 | ELANE (0.58) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL6246856 | 0.79 | DDAH1 (0.56) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL4825241 | 0.79 | DDAH1 (0.56) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL12774716 | 0.79 | DDAH1 (0.56) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL303847 | 0.79 | ELANE (0.58) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| SCHEMBL16238149 | 0.79 | DDAH1 (0.56) | DDAH1ADRA2CALDH1A1KMT2ALMNA | |
| Iodide SCHEMBL2761751 | 0.78 | ELANE (0.56) | DDAH1ADRA2CALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | claimed |
| CN-114127181-B | Thermoplastic resin composition and molded article thereof | 大科能宇菱通株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-114127181-A | Thermoplastic resin composition and molded article thereof | 大科能宇菱通株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2009082686-A1 | COMPOSITIONS AND METHODS FOR USING ASYMMETRIC DISULFIDES | PROLX PHARMACEUTICALS CORP. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-1786477-A2 | METHOD OF PRESELECTION PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | Prolx Pharmaceuticals Corp. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-18 | — | — | US | disclosed |
| WO-2006023658-A2 | METHOD OF PRE-SELECTING PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | PROLX PHARMACEUTICALS CORP. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005007108-A2 | ASYMMETRIC DISULFIDES AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040116496-A1 | Asymmetric Disulfides and methods of using same | PROLX PHARMACEUTICALS CORP. | 2004-06-17 | — | — | US | disclosed |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | disclosed |
| US-6552060-B1 | Inhibits abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis | PROLX PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | HIF1A, TXNRD3, HIF1AN | DDAH1 737/4885ADRA2C 3891/4885ALDH1A1 1044/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | DDAH1 659/4885ADRA2C 2968/4885ALDH1A1 143/4885 |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PRDX3, PDIA5, PRDX5 | DDAH1 937/4885ADRA2C 4772/4885ALDH1A1 2098/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | DDAH1 659/4885ADRA2C 2968/4885ALDH1A1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.